Search Bar & Filters
Found 28 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Researchers are studying the effects of combining an experimental drug called fianlimab REGN3767 with cemiplimab, compared to cemiplimab with a placebo, in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC that has not been previously treated. The study focuses on patients whose cancer is positive for PD-L1 expression and aims to understand side effects, drug levels in the blood, and immune responses to the treatments. Participants are divided into two groups based on HPV status one with HPV-positive HNSCC and the other with HPV-negative HNSCC. Each group is randomly assigned to receive either the combination of fianlimab and cemiplimab or cemiplimab with placebo. Both treatments are given as fixed-dose combinations according to the study protocol. During the study, participants will be monitored for up to about 58 months, including assessments of overall response rate, disease control, progression-free survival, and duration of response. Researchers will also track various types of adverse events and measure drug concentrations and antibody responses in the blood. Safety and treatment effects will be evaluated throughout and up to 90 days after the last treatment dose.
Actively Recruiting
This research aims to collect long-term safety and disease progression data on patients diagnosed with atypical hemolytic-uremic syndrome aHUS, including those treated or untreated with the drugs eculizumab or ravulizumab. The study is observational and involves multiple centers and countries, focusing on real-world information after these treatments have been marketed. Participants include patients of any age diagnosed with aHUS, regardless of whether they have identified complement genetic variants or antibodies. The study gathers data without administering new treatments, monitoring patients who may or may not have received eculizumab or ravulizumab. The registry collects information over extended periods to understand safety events and disease course. During the study, researchers track safety-related events over 10 years and the timing of these events within 5 years. Data collection involves reviewing patient health status and disease progression without altering their usual care. The study relies on informed consent and may include minors with appropriate assent. Participation duration varies, with continuous observation to gather comprehensive post-marketing safety data.
Actively Recruiting
Researchers are evaluating several treatments for adults with kidney failure who have recently been diagnosed with calciphylaxis, a rare disease affecting about 1 to 2 people in 10,000. This phase 3 global platform trial aims to provide high-quality evidence on the effects of different therapies across various care areas. The study uses an adaptive design to add or remove treatment options based on ongoing results, improving how patients with this condition are treated. The trial begins with two main treatment areas the Dialysis Membrane Domain and the Pharmacotherapy Domain. In the Pharmacotherapy Domain, participants receive either Vitamin K1 capsules, Magnesium Citrate tablets, Sodium Thiosulfate injections, or placebos, with dosing schedules matched to their dialysis sessions. The Dialysis Membrane Domain compares two types of dialysis filters, high flux and medium cut-off dialysers, in an open-label design. Treatments are given according to these schedules, and new interventions may be added as the trial progresses. Participants will be monitored and assessed using the BEAT-Calci Wound Assessment Scale over 12 weeks as the primary outcome, with additional evaluations up to 26 weeks and beyond. Assessments include wound measurements, pain levels, analgesic use, quality of life, infection rates, hospital days, mortality, kidney transplantation status, and calciphylaxis recurrence. The study uses a Bayesian adaptive approach to adjust sample size and study arms based on collected data, continuing until clear results on treatment effects are reached.
Actively Recruiting
Neuroendocrine tumours NETs are slow-growing cancers often found in the gut that can spread to organs like the liver, bones, and lymph nodes. Many NETs do not produce excess hormones, and their main treatment is somatostatin analogues SSA, which slow tumour growth and reduce hormone production. Over time, most patients experience tumour growth despite SSA therapy. This study investigates whether continuing SSA treatment after starting Peptide Receptor Radionuclide Therapy PRRT, a targeted radiotherapy, benefits patients with grade 1 and 2 well-differentiated mid, hind-gut, or pancreatic NETs that have progressed on SSA therapy. Participants will be randomly assigned to one of two groups those who continue SSA injections during and after PRRT, and those who stop SSA after receiving their last injection before starting PRRT. PRRT is given as the next treatment step for patients with inoperable metastatic NETs who have shown progression despite SSA therapy. The study aims to estimate the 20-month progression-free survival rate for both groups and assess feasibility factors like recruitment and patient acceptance of stopping SSA. During the study, patients will receive PRRT and either continue or cease SSA injections according to their group assignment. Researchers will monitor tumour progression, quality of life, cost-effectiveness, psychological impacts, overall survival, and the timing of any further treatments over 20 months. Study assessments include imaging scans, performance status evaluations, and collection of clinical data. This trial is open-label and will help clarify the role of continuing SSA therapy alongside PRRT in this patient population.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are studying patients with metastatic melanoma to compare two ways of giving PD-1 inhibitor therapy, a type of immunotherapy that helps the immune system fight cancer. The study aims to find out if taking PD-1 inhibitors intermittently with breaks works as well as continuous non-stop treatment in extending patients lives. This is a Phase III randomized trial led by the Canadian Cancer Trials Group. Participants receive PD-1 inhibitors that are government approved and publicly funded, with doses recommended by the manufacturer. One group takes the treatment continuously for up to two years, while the other takes it intermittently, with breaks when the melanoma improves. The trial compares these two treatment schedules to see if intermittent therapy can provide similar benefits with potentially fewer clinic visits, side effects, and costs. During the study, participants will be monitored over seven years to assess overall survival as the main outcome. Researchers will also measure progression-free survival, response rates, duration of response, side effects, quality of life, and economic impact using questionnaires and clinical evaluations. Participants must complete quality of life questionnaires in English or French and be available for treatment and follow-up visits throughout the study period.
Actively Recruiting
Researchers are evaluating epoetin alfa, a medication related to erythropoiesis stimulating agents, in critically ill trauma patients who require mechanical ventilation in intensive care units ICUs. This phase III, randomized, double-blind trial aims to see if epoetin alfa can reduce death rates and severe disability six months after injury. The study involves 2500 patients admitted to ICUs with primary trauma diagnoses from centers in Australia, New Zealand, Europe, and Saudi Arabia. Participants will receive either epoetin alfa 40,000 IU or a placebo sodium chloride 0.9% by subcutaneous injection on Study Days 1 and 8 while in the ICU. Treatment is administered during their ICU stay, and patients are randomly assigned to one of these two groups. The study is designed to compare the effects of epoetin alfa against placebo in this critically ill population. During the study, patients will be monitored for survival and disability outcomes using tools like the World Health Organization Disability Assessment Schedule WHODAS 2.0 at six months. Other outcomes include mortality at different time points and thrombotic vascular events. Data on clinical status, adverse events, and safety will also be collected. The total participation length includes ICU stay and follow-up assessments up to six months after injury.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating ways to improve hepatitis C virus HCV care in drug treatment clinics and needle and syringe programs in New South Wales and across Australia. The ETHOS II Project aims to develop a framework to establish HCV screening and treatment programs in these settings nationally. This collaborative research involves several health organizations and focuses on people with a history of injecting drug use or those receiving opioid substitution therapy. The study includes an intervention called campaign days where participants receive hepatitis C screening, liver fibrosis assessments using fibroscans, and clinical assessments. Participants also complete surveys and may consent to link their data with population databases. A sub-study involves collecting blood samples from some participants to evaluate new diagnostic tests for chronic HCV infection. Additionally, interviews with policymakers, clinicians, and patients will explore barriers to HCV care, and an education program will be developed to improve workforce knowledge and care quality. Participants will be recruited from drug treatment clinics, general practitioners with high case loads, and needle and syringe programs. They will undergo hepatitis C testing, fibroscans, clinical assessments, and complete questionnaires during the campaign days. Researchers will track how many participants start anti-HCV treatment each year for up to three years. The study also includes follow-up through medical record reviews to monitor outcomes and improve treatment access and delivery.
1-10 of 28
1